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Very elderly patients (i.e., ≥80 years) are disproportionally affected by acute ischemic
stroke. They account for a third of hospital stroke admissions, but two-thirds of overall
stroke-related morbidity and mortality.There is some evidence of clinical benefit in treating
selected very elderly patients with intravenous thrombolysis (IVT). For very elderly patients
ineligible or non-responsive to IVT, intra-arterial therapy (IAT) may have promise in improv-
ing clinical outcome. However, its unequivocal efficacy in the general population remains
to be proven in randomized trials. Small cohort studies reveal that the rate of good clinical
outcome for very elderly patients after IAT is highly variable, ranging from 0 to 28%. In
addition, they experience higher rates of futile reperfusion than younger patients. Thus,
it is imperative to understand the factors that impact on clinical outcome in very elderly
patients after IAT.The aim of this review is to examine the factors that may be responsible
for the heterogeneous clinical response of the very elderly to IAT.This will allow the reader
to integrate the current available evidence to individualize intra-arterial stroke therapy in
very elderly patients. Placing emphasis on pre-stroke independent living, smaller infarct
core size, short procedure times, and avoiding general anesthesia where feasible, will help
improve rates of good clinical outcome.
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INTRODUCTION
Almost one-third of new ischemic strokes occur in patients aged
80 years or older (1). In this very elderly cohort, ischemic stroke is
associated with more severe neurological impairment and higher
morbidity and mortality rates, compared to non-elderly patients
(2). The Third International Stroke Trial (IST-3) demonstrated
the likely clinical benefit of intravenous thrombolysis (IVT) in
very elderly stroke patients (3). For patients ineligible or non-
responsive to intravenous thrombolysis, intra-arterial therapy
(IAT) may have promise in improving clinical outcome. How-
ever, its efficacy in younger stroke patients remains to be proven
in randomized trials. Cohort studies reveal that the rate of good
clinical outcome after very elderly patients are treated with IAT is
heterogeneous, ranging from 0 to 28% (4–10). In addition, close
to 50% of elderly patients experience futile reperfusion, i.e., 90-
day follow-up modified Rankin scale (mRS) score of 3–6, despite
thrombolysis in cerebral infarction (TICI) 2B-3 reperfusion and
Abbreviations: DNR, do not resuscitate; ECASS, European Cooperative Acute
Stroke Study; IAT, intra-arterial therapy; IST-3, Third International Stroke Trial;
IVT, intravenous thrombolysis; ivtPA, intravenous tissue plasminogen activator;
mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale;
NINDS, National Institute of Neurological Disorders and Stroke; sICH, sympto-
matic intracranial hemorrhage; SITS-MOST, Safe Implementation of Thrombolysis
in Stroke-Monitoring Study; SWIFT, Solitaire With Intention for Thrombectomy;
TICI, thrombolysis in cerebral infarction; TREVO2, Trevo vs. Merci retrievers for
thrombectomy revascularization of large vessel occlusions in acute ischemic stroke.
no intracranial hemorrhage (11). This is almost double the rate of
futile reperfusion for younger patients. These facts could lead to
treating physician reluctance to offer very elderly patients intra-
arterial stroke therapy. Thus, to individualize intra-arterial stroke
therapy decisions in very elderly patients, there is a critical need to
understand the factors that impact on clinical outcome.
The aim of this focused review is to examine the factors that
may be responsible for this heterogeneity in clinical outcome in
this growing population of very elderly stroke patients undergoing
IAT. This will allow the reader to integrate the current available evi-
dence with their own clinical expertise and patient wishes to make
the most appropriate clinical decision for very elderly patients
being considered for intra-arterial stroke therapy.
WHY EXAMINE OUTCOMES IN VERY ELDERLY PATIENTS?
The worldwide incidence of first-ever stroke in 2005 was estimated
at 16 million, with 5.7 million stroke-related deaths (12). This is
expected to rise to 23 million strokes and 7.8 million deaths by 2030
(12). This increase is largely driven by the rapidly growing elderly
population – in the United States, the population aged greater
than 85 years is expected to increase fivefold by 2050 (13). These
expanding numbers of the very elderly will produce an increasing
burden of age-associated disease, mandating a clear understanding
of treatment options for this population.
After ischemic stroke admission, very elderly patients experi-
ence greater disability and are less likely to be discharged home,
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even if they receive similar rates of stroke care quality metrics as
younger patients (14). Despite treatment with either IVT or IAT,
there remain higher rates of in-hospital mortality than younger
patients (15). Even after adjustment for differences in stroke risk
factors and comorbidities, they continue to have poorer functional
outcomes (2). Ultimately, elderly patients account for only one-
third of all admissions but almost two-thirds of all stroke deaths
(2). This disproportionate effect of ischemic stroke on the elderly
will continue to grow significantly in the future.
WHAT HAVE WE LEARNED LATELY ABOUT ACUTE STROKE
THERAPY IN ELDERLY PATIENTS?
For many years, there has been a paucity of high quality evi-
dence for acute stroke therapy in elderly patients. Only 42 elderly
patients were included in The National Institute of Neurological
Disorders and Stroke (NINDS) intravenous tissue plasminogen
activator (ivtPA) trial (16, 17) and they were excluded from the
large IVT trials such the European Cooperative Acute Stroke Study
(ECASS) III (18) and Safe Implementation of Thrombolysis in
Stroke-Monitoring Study (SITS-MOST) (19).
A previous non-randomized controlled comparison of the
SITS-International Stroke Thrombolysis Registry and Virtual
International Stroke Trials Archive included 3,439 very elderly (age
>80) patients (total n= 29228) (20). Although increasing age was
associated with poorer outcome, the association between throm-
bolysis and improved outcome was maintained in very elderly
patients. Recently, the results of the IST-3, an international multi-
center randomized controlled trial of IVT within 6 h of ischemic
stroke onset, were published (3). This included the largest cohort
of elderly patients in a randomized controlled IVT trial to date (age
>80; n= 1617; total n= 3035). Although IST-3 failed to reach its
primary endpoint, secondary analysis revealed that treatment ben-
efit was greatest in the 0–3 h cohort, with 30.6% of those treated
with ivtPA alive and independent at 6 months compared to 22.7%
of controls. The vast majority (n= 726/849) included in this 0–
3 h cohort were >80 years, and the treatment benefit in patients
>80 years was at least as large as younger patients. Thus, potential
treatment benefit from IVT does likely extend to elderly patients.
In contrast, there is no high quality randomized controlled
data reporting on clinical outcomes of IAT in the elderly. The
large IAT trials, including the recent three trials published in the
New England Journal of Medicine, all excluded elderly patients
greater than 85 years or did not reported age-related outcomes
(21–28). The smaller case cohort studies have all reported quite
variable clinical outcomes. As defined by 90-day mRS≤2, the rates
of good clinical outcome in elderly patients range from 0 to 28%
(4–10). Table 1 summarizes data from current published stud-
ies designed to assess clinical outcome after very elderly patients
with anterior circulation stroke are treated with IAT. These stud-
ies include patients treated with intra-arterial thrombolysis, and
older generation mechanical devices such as the Merci Retrieval
System (Concentric Medical, Mountain View, CA, USA) and the
Penumbra System (Penumbra,Alameda, CA, USA) that have lower
reperfusion rates compared to modern intra-arterial stentrievers.
There is a paucity of data on outcomes of elderly patients
treated with these stentriever devices – the Solitaire With Inten-
tion for Thrombectomy (SWIFT) and Trevo vs. Merci retrievers for
thrombectomy revascularization of large vessel occlusions in acute
ischemic stroke (TREVO2) trials excluded patients>85 years, and
no age-stratified outcomes for older patients have been reported
(31, 32). The large prospective single-arm study of patients with
large vessel anterior circulation strokes treated using the solitaire
FR stentriever also excluded patients aged >84 years (33). Simi-
larly, the prospective European TREVO trial excluded those aged
>85 years (34).
Notably, a recent abstract published from the North Ameri-
can Solitaire Stent Retriever Acute Stroke registry did include 64
very elderly patients and compared outcomes to 245 non-elderly
patients (35). Despite similar rates of reperfusion (TICI≥ 2a)
and symptomatic intracranial hemorrhage (sICH), very elderly
patients had significant lower rates of good clinical outcome (90-
day mRS ≤2: 27 vs. 45%; P = 0.007) and higher mortality (42 vs.
27%:P = 0.03) compared to younger patients. The Trevo Retriever
Registry has also been recently launched in the US to assess the real
world performance of the Trevo Retriever. There is no upper age
limit, and this will provide further data for the very elderly cohort.
WHY ARE CLINICAL OUTCOMES HETEROGENEOUS?
There are many factors that impact on the clinical outcome of
patients undergoing IAT. In elderly patients, pre-stroke disability,
baseline infarct size, cerebral collateral circulation, use of general
anesthesia, and procedural time are prominent factors. In addi-
tion, there are concerns that very elderly patients have higher rates
of post-treatment hemorrhage, and significant differences in post-
treatment care that could negatively impact on clinical outcome.
So what have we learnt lately?
PRE-STROKE DISABILITY
Pre-stroke disability and institutionalization (not living at home)
are independent predictors of post-stroke death and disability in
elderly stroke patients (1, 36). These are common in the elderly
stroke cohort – almost half of elderly patients hospitalized for
index stroke have a pre-stroke mRS of 2–5, while one in seven
are institutionalized prior to admission (1). In spite of these facts,
most studies of IAT in elderly patients have not reported rates of
baseline disability and institutionalization. Approximately, one-
third of the single center elderly cohort reported by Chandra et al.
had baseline mRS>1; 2% of patients had a good clinical outcome
(5). Thirteen percent of the cohort examined by Kurre et al. had
pre-stroke mRS scores of 3–4; 17% of the overall cohort had a good
clinical outcome (7). Patients with baseline mRS scores >1 were
excluded from the cohort by Mono et al.; 28% of elderly patients
had a good clinical outcome (9). Nevertheless, elderly patients had
significantly lower rates of good clinical outcome and higher rates
of mortality than younger patients in both cohorts, suggesting
that there are additional factors responsible for the worse clinical
outcomes among the very elderly.
BASELINE INFARCT SIZE
There are emerging data that elderly stroke patients require smaller
baseline infarcts to achieve good clinical outcome when compared
to younger patients. In patients undergoing IAT, final infarct vol-
ume is a powerful predictor of clinical outcome (37, 38). With
increasing age, the post-treatment infarct volume that predicts
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Table 1 | Summary of current published studies designed to assess clinical outcome after very elderly patients with anterior circulation stroke
undergo IAT.
Author
(year)
Age used to
define elderly
cohort
Number of
very elderly
patients
Number of
younger
controls
sICH rate
in elderly
cohort
Primary
outcome
measures
Summary of primary outcome
Singer
et al. (11)
77 Registry of
362 patients;
25% of cohort
>76; 91
patients
Registry of
362 patients;
75% of cohort
18–76 years;
271 patients
Not reported;
3% ECASS
parenchymal
hematoma
type II in total
cohort
90-day mRS
and “futile
recanalization”
Outcome is age-dependent with elderly patients (in
the highest age quartile of 77–94 years) having the
lowest rates of good outcome (mRS 0–2) of 17%
compared to 60% for patients in the lowest age
quartile (18–56 years). Elderly (77–94 years)
patients had higher rates (46 vs. 24%) of clinically
“futile recanalization” (defined as 90-day mRS
score ≥3 despite successful recanalization and no
subsequent hemorrhage) compared the lowest age
quartile (18–56 years)
Kurre
et al. (7)
80 109 0 6% ECASS
parenchymal
hematoma
type II
90-day mRS 13% had pre-stroke disability of mRS score 3–4. By
90 days, 17% of elderly patients had a mRS score
0–2; mortality rate was 48%
Willey
et al. (15)
80 186 622 Not reported In-hospital
mortality
Very elderly patients had a higher risk of in-hospital
mortality compared with younger counterparts
regardless of treatment modality (IAT and/or IVT)
(OR, 2.13; 95% CI, 1.60–2.84). IAT does not
increase the risk of in-hospital mortality in very
elderly patients compared to IVT alone
Chandra
et al. (5)
80 49 130 4% ECASS
parenchymal
hematoma
type II
90-day mRS
and mortality
Very elderly patients had significantly lower rates of
good outcome (mRS 0–2: 2 vs. 33%; P <0.0001)
and higher mortality (59 vs. 24%; P <0.0001) at
90 days compared to younger patients
Mono
et al. (9)
80 43 524 2% 90-day mRS
and mortality
Very elderly patients had significantly lower rates of
good outcome (mRS 0–2: 28 vs. 46%; P =0.019)
and higher mortality (40 vs. 22%; P =0.0008) at
90 days compared to younger patients
Ghobrial
et al.
(29)
75 51 patients
aged 75 or
greater
0 6% Discharge
mRS
At time of discharge, 33% of elderly patients had a
mRS score 0–3; mortality rate at discharge was
22%
Arkadir
et al. (4)
80 14 66 7% 90-day mRS Very elderly patients had significantly lower rates of
good outcome (mRS 0–2: 0 vs. 41%; P =0.008)
Mazighi
et al. (8)
80 25 59 12% 90-day mRS Very elderly patients had significantly lower rates of
good outcome (mRS 0–2: 28 vs. 64%; P =0.002)
and higher mortality (40 vs. 22%; P =0.002) at
90 days compared to younger patients
Loh
et al.
(30)
80 31 75 11% mRS at
discharge and
stroke-related
death
Very elderly patients had lower rates (not
statistically significant) of good outcome (mRS 0–2:
19 vs. 33%; P =0.17) at discharge compared to
younger patients. Rates of stroke-related death
were significantly higher in elderly patients (48 vs.
15%; P =0.0005) at discharge compared to
younger patients
(Continued)
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Table 1 | Continued
Author
(year)
Age used to
define elderly
cohort
Number of
very elderly
patients
Number of
younger
controls
sICH rate
in elderly
cohort
Primary
outcome
measures
Summary of primary outcome
Qureshi
et al. (10)
80 24 77 8% 30–90 day
mRS and
mortality
Very elderly patients had lower rates (not
statistically significant) of good outcome (mRS 0–2:
21 vs. 38%; P =0.21) at 30–90 days compared to
younger patients. There were higher rates of
mortality (54 vs. 29%; P =0.02) as compared to
younger patients
Kim
et al. (6)
80 33 81 7% 90-day mRS Very elderly patients had significantly lower rates of
good outcome (mRS 0–2: 26 vs. 40%; P =0.02)
and higher mortality (43 vs. 20%; P =0.01) at
90 days compared to younger patients
All studies included small numbers of posterior circulation stroke patients, with the exception of Singer et al. (11), Chandra et al. (5), and Arkadir et al. (4) who only
included anterior circulation stroke.
good clinical outcome reduces (39). Target cut-off infarct volume
for predicting a good clinical outcome calculated from 24-h post
procedure CT scans suggests volumes of approximately<50 cc for
patients <70 years; <30 cc for patients 70–79 years; and <15 cc
for those ≥80 years (39). This is not surprising as elderly patients
have lesser neurological rehabilitation potential (40) and higher
rates of in-hospital medical complications after stroke, which is a
predictor for death and disability in elderly patients (36). None
of the current studies of IAT in the elderly report on exact base-
line infarct volumes. While intra-arterial selection criteria based
on baseline MR imaging may be able to accurately stratify these
volume thresholds, this is unlikely to occur with sufficient accu-
racy using non-contrast CT or CT perfusion-based intra-arterial
selection strategies, particularly early after symptom onset (41, 42).
COLLATERAL CIRCULATION
There are conflicting data on whether elderly stroke patients with
anterior circulation occlusion have poorer leptomeningeal collat-
erals than younger patients. Collateral circulation can sustain the
ischemic brain tissue after vessel occlusion, and determines how
quickly an infarct grows to complete its course. Patients with good
collaterals typically have smaller baseline infarcts and higher rates
of recanalization if treated with IAT (43, 44). If successful reper-
fusion occurs (TICI 2b-3), infarct growth is attenuated, and a
higher rate of good clinical outcome can be achieved (43, 44). It
has also been reported that every 10-year increment in age almost
doubles the odds of inadequate collateral circulation (45). Pro-
viding further support for this hypothesis of poorer collaterals
in older patients, collateral augmentation improved outcome in
elderly stroke patients in the recent safety and efficacy of Neu-
roFlo Technology in ischemic stroke trial (46). A good clinical
outcome at 90 days was two to four times more likely in elderly
patients treated with intermittent partial aortic balloon occlu-
sion to augment cerebral blood flow and collateral circulation in
a sub-group of patients older than 70 years. There was greater
benefit for patients aged 80 years and older, while no benefit was
observed in patients younger than 70 years. This demonstrates the
importance of the collateral circulation, particularly in the elderly
stroke patient.
ANESTHESIA
The use of general anesthesia has been linked to poorer outcomes
in patients undergoing IAT (47, 48) which may be accentuated in
elderly patients. The exact mechanism of poorer outcome after
general anesthesia is unclear. There is a major confounder in the
data published, as baseline National Institutes of Health Stroke
Scale (NIHSS) scores were higher in the general anesthesia cohort.
However, in a sub-group analysis of 494 patients (total n= 1079),
controlling for NIHSS, general anesthesia remained a predictor for
poor outcome (47). The major postulate to explain this phenom-
enon is post-induction or intra-procedural reduction in blood
pressure impacting on cerebral collateral perfusion. This is sup-
ported by the recent report that maintaining a lowest systolic blood
pressure of >140 mmHg is an independent predictor of good
neurological outcome after IAT (49). Post-induction hypotension
occurs more often in older patients, which could contribute to
poorer outcomes (50). In current reports of the elderly undergo-
ing IAT, the rate of usage of general anesthesia range from 40 to
100% (5, 9, 11, 29), so this may be a significant factor affecting the
currently published rates of good outcome.
Furthermore, it has also been shown that early neurocognitive
dysfunction is common in patients undergoing carotid endarterec-
tomy under general anesthesia (51). This phenomenon occurs at
a significantly higher rate in older patients (51). Interestingly, ele-
vation of intra-operative mean arterial blood pressure during the
cross-clamp period during endarterectomy significantly reduced
the incidence of this phenomenon, presumably by optimization of
cerebral collateral perfusion (52). Thus, the elderly stroke patient
with a large vessel occlusion may be particularly vulnerable to the
negative effects of hypotension and general anesthesia during IAT.
PROCEDURAL TIME
Vascular tortuosity and atherosclerotic burden in the elderly stroke
population may contribute to longer procedural times that in turn
negatively impacts on clinical outcome. Although no study has
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found a statistically significant difference in symptom onset to
start or conclusion of IAT in elderly patients compared to younger
patients (5, 6, 9, 30), older age is associated with longer time to
access the target carotid artery in anterior circulation stroke (53).
In the quarter of the total cohort (n= 130) where vessel tortuosity
resulted in greater than 30 min delay in placing the guide catheter
into the target carotid artery, there was a significant reduction
in the rate of reperfusion and good neurological outcome com-
pared to those with faster target vessel access. Notably, there was
no difference in the time from symptom onset to final reperfusion.
POST-TREATMENT HEMORRHAGE
There is often concern that elderly patients have higher rates of
post-procedural hemorrhage compared to younger patients that
could lead to futile reperfusion by worsening patient outcome
or causing in-hospital mortality. However, in the cohort stud-
ies of elderly patients undergoing IAT, there were no significant
differences in the rates of parenchymal hematoma (PH) type 2
[ECASS definition (54)] or sICH (5, 6, 8, 9, 30). The concern may
be in part due to the variability in definitions used in these stud-
ies and the small patient numbers. In an analysis of greater than
22,000 patients undergoing IVT, although there was no difference
in the rates of elderly patients experiencing sICH according to the
SITS-MOST definition, the rates of sICH according to the NINDS
definition were significantly higher (20). Nonetheless, in a large
cohort study of anterior circulation stroke patients undergoing
IAT (n= 1122), age was not a predictor of intracranial hemor-
rhage after IAT (55). Furthermore, in a large study of IAT in
elderly patients (n= 1182), IAT did not increase the rates of in-
hospital mortality compared to intravenous thrombolysis alone
(15). Thus, it does not seem that the worse clinical outcomes and
higher mortality rates seen in elderly patients are attributable to
post-procedural hemorrhage.
POST-TREATMENT CARE
Elderly patients are more likely to have greater neurological
impairment, swallowing difficulty, confusion, and urinary inconti-
nence during hospitalization for acute stroke compared to younger
patients (1). These are all risk factors for the development of pneu-
monia, which accounts for up to third of in-hospital deaths after
ischemic stroke (56). In addition, elderly patients often have “do
not resuscitate (DNR)”orders in place. In spite of these referring to
patient wishes regarding cardiopulmonary resuscitation, the pres-
ence of these orders also leads to an overall reduction in physician
willingness to treat (57). After hemorrhagic stroke, the presence of
a DNR order leads to significantly reduced rates of guideline rec-
ommended care, including stroke unit care (58). For the elderly
patient experiencing a severe stroke, the development of pneumo-
nia or lack of guideline recommended care could contribute to
poorer outcomes compared to younger patients.
FUTURE DIRECTIONS
The reality is that an ischemic stroke occurring in an elderly patient
is a severe life-threatening event. After their first-ever ischemic
stroke, a third of elderly patients are likely to be dead within 30 days
(59). Even after 12 months, only a quarter have improved to mild
or no disability. In light of the frailty of the elderly population,
we may be unrealistic in our expectations that a high proportion
of elderly patients will have minimal disability after IAT. The data
that are currently available suggest that the clinical outcomes in
elderly patients undergoing IAT are heterogeneous, however rates
of no or mild disability as high as 28% have been reported. More-
over, performing IAT in the elderly has not raised safety concerns,
particularly with regard to post-treatment hemorrhage.
In light of the findings summarized in this review, individu-
alized patient selection for IAT appears more important in the
elderly stroke patient. Emphasis needs to be placed on pre-stroke
independent living, smaller infarct core size, short procedure
times, and avoiding general anesthesia where feasible. Multidis-
ciplinary screening and treatment protocols for post-stroke pneu-
monia with minimization of ventilator time will be also important
in optimizing outcomes. In the future, invasive techniques for col-
lateral augmentation may be found to have particular benefit in
the elderly. Most importantly, while we must be realistic in our
expectations of clinical outcome, we should also not deny elderly
patients’ guideline recommended care. As selection criteria for
IAT in the elderly are refined, and with more rapid and complete
reperfusion, the clinical outcome of elderly patients treated with
IAT should improve.
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